Introduction

Breast cancer has the highest rate of new cancer diagnoses and is the second most common cause of cancer-related deaths in the state of Arkansas [1]. Both breast and thyroid cancer rank in the top 10 cancers with the highest rates of incidence in Arkansas and nationwide over the period of 2012-2016 (Figure 1). Incidence rates are similar between the Uniteded and the state of Arkansas, and breast and thyroid cancer rank as 1 and 5, respectively.

Women who are diagnosed with breast cancer routinely undergo surveillance for metastatic disease and may be found incidentally to have thyroid pathology. Recent studies suggest that a link between breast and thyroid cancer exists [2-5]. This trend warrants serious consideration on the part of professional medical societies and clinicians to consider follow up for thyroid nodules in patients already diagnosed with breast cancer. Conversely, the opposite vigilance might apply for breast lumps in thyroid cancer patients [6]. Over the years 2000-2017, the SEER database shows that incidence of breast cancer has remained steady, while the incidence of thyroid cancer has steadily risen (Figure 2).

Interest among this paper’s authors on the topic resulted from experience with common clinical scenarios such as the following. A middle-aged female who had been diagnosed and treated for breast cancer would undergo post therapy surveillance for recurrence with whole body 18 FDG Positron emission tomography (PET) scanning. These scans on occasion would show thyroid gland uptake above background levels, which would prompt referral from the breast surgeons to the thyroid surgeons. PET positivity within the thyroid gland would be of 2 types, diffuse or focal [7-10].

Diffuse thyroid uptake on PET is reflective of autoimmune thyroid disease (Hashimoto’s Thyroiditis) and is confirmed by thyroid function and antibody testing [11,12]. These patients are then treated appropriately and returned to the care of the breast and primary care teams. Patients with focal thyroid uptake on PET are evaluated according to the latest American Thyroid Association (ATA) guidelines for thyroid nodules [13]. This typically includes thyroid function testing (to rule out hyperthyroidism), ultrasonography of the thyroid and cervical lymphatics, and ultrasound directed fine needle aspiration biopsy for a cytologic diagnosis of the nodule(s) and any lymph-
adenopathy which might be present and be of sonographic concern. Cytology results are managed expectantly based on their Bethesda classification and a surgical treatment plan is formulated [14,15].

Based on our interest generated by events in our clinical practice, and a longstanding interest in PET positive thyroid lesions [7-10], we decided to examine our data with respect to this clinical phenomenon. This also raised the question as to whether an absolute prohibition of thyroid nodule screening among current guidelines might need amendment for cases of breast cancer survivors. Therefore, this study examines the association between women diagnosed with breast cancer in Arkansas who also had thyroid pathology, including benign thyroid disease.

Materials and Methods

The Arkansas Breast Cancer database was cross-referenced with records in UAMS’ EPIC EMR, which went live in May 2014, to identify women who were diagnosed with both breast cancer and thyroid disease as of the date the data was extracted, which was August 6, 2019. A chart review was then conducted to collect dates of diagnosis, histologic subtypes, treatment, patient demographics, and other data on 276 patients with both breast cancer and thyroid pathology. Of the 276 patients with both breast cancer and thyroid pathology, 2 did not have dates of diagnosis for their breast cancer, and so these cases were not included in the statistical analyses using dates or ages at diagnosis. Upon completion of chart review, descriptive statistics such as means and standard deviations, among others (medians, lower and upper quartiles, minimums and maximums), were calculated for continuous variables such as patients’ ages tabulated at breast/thyroid cancer diagnoses. Counts and percents were reported for histologic subtypes of breast and thyroid cancers (categorical variables). Data analyses were conducted using SAS v9/4 (SAS Institute; Cary, NC). The relative

Figure 1: Top 10 cancers by rates of new cancer cases in the United States and Arkansas.

Figure 2: Breast and thyroid cancer incidence rates among women in the Arkansas Cancer Registry and SEER 21 database.
risk (also known as the risk ratio) was also calculated, which is the ratio of the probability of an outcome in an exposed group to the probability of an outcome in an unexposed group. An exposed group in our study is patients with breast cancer diagnosis while unexposed group contains patients without breast cancer diagnosis. The outcome of interest is thyroid cancer diagnosis. The relative risk was calculated using PROC FREQ with option of “relrisk” using SAS v9.4 software.

### Results and Discussion

#### Results

There were 264,887 women who had an appointment with an otolaryngologist found in the EPIC data source since May 2014. Based on this sample, there were 5,645 women who had a diagnosis of breast cancer and 1,414 women who had a diagnosis of thyroid cancer during the same time period. Out of 5,645 women with a diagnosis of breast cancer, 25 (0.44%) women also had thyroid cancer diagnosed after breast cancer. Out of the remaining 259,242 women without a breast cancer diagnosis, 1,389 (0.54%) women were diagnosed with thyroid cancer. The average age at breast cancer diagnosis among 274 women was 56-years-old, while the average age at thyroid cancer diagnosis was 54-years-old. The most common histologic subtype of breast cancer among 276 women was invasive ductal carcinoma (46%), and more than two-thirds (68%) of women had papillary thyroid cancer histology.

The women in this study were at a 17% lower risk of developing thyroid cancer after breast cancer compared to those women without history of thyroid cancer (RR: 0.50; 95% CI: 0.30-0.83). Descriptive statistics for both groups are summarized in Table 1. Histologic subtypes for breast cancer are given in Table 2, and subtypes for thyroid cancer are given in Table 3. All patients were female, and demographics for race and ethnicity are given in Table 4.

#### Discussion

Cancer, in general, is understood to be a disease with a pathogenesis that is fundamentally genetic, whether it arises from damage to DNA (inherited or environmentally caused) in individual cells, or from missing or defective gene copies or gene products (proteins) that regulate expression or control cell proliferation. As such, researchers increasingly find that certain types of cancers tend to occur in clusters. Examples include Lynch syndrome, BRCA1 and BRCA2, MEN syndromes, and many others [16].

The clinical scenario outlined in the introduction of this paper occurred often enough to prompt the authors to take notice and ask whether thyroid and breast cancer share an association that may be rooted in a common etiology. If such an association were found to exist, it would impact recommendations on screening breast cancer survivors for thyroid cancer. Additionally, establishment of any associations would alert clinicians to risks that need to be considered in the care of these cancer patients.

As treatment for cancer has improved, more patients are...
surviving to develop recurrence and second primary cancers [17-23]. In 2006, the Institute of Medicine called for the creation of survivorship care plans for cancer survivors to address these patients growing long-term care needs [23]. The Childhood Oncology Group (COG) and American Cancer Society (ACS) responded by providing evidence-based guidelines for clinicians to refer to in creating these plans for their patients [17-21,24]. The COG guidelines recommend screening for second primaries in survivors of childhood, adolescent, and young adult cancers, specifically for breast and colorectal cancers [24]. The ACS developed survivorship guidelines for 4 primary cancers, namely breast, colorectal, prostate, and head and neck cancer (HNC) [18-21]. HNC included cancers caused by HPV or smoking, not the thyroid [21], and this set of survivors was the only group for whom the ACS considered the primary cancer a factor that placed them at greater risk than the general public. For HNC survivors, the ACS recommends additional screening for lung cancer [21].

For all other cancer survivors, ACS guidelines state that those with average risk undergoes the same screening for second primary cancers (SPC) as the general public [17-20]. Patients with high risk for cancers are recommended to undergo additional imaging [17-20]. Per the ACS, breast cancer survivors are considered high risk if they have a strong family history of breast cancer, a genetic mutation such as BRCA1 or BRCA2, or if they received radiation therapy for another cancer, such as Hodgkin lymphoma [25]. Yet there is a growing body of evidence that suggests these guidelines may be incomplete, and that clinicians should have a higher level of suspicion that their breast cancer patient may have, or may yet develop, a second primary thyroid malignancy [2-5,26].

A higher than expected incidence of thyroid cancer has been observed in breast cancer patients. One recent meta-analysis reports an odds ratio (OR) of a female developing thyroid cancer after a breast cancer to be 1.55 (expected OR 1.0 in the general population) [2]. With this increased incidence having been observed, many have begun to speculate on the impact that routine thyroid cancer screening would have on this select patient population [2,27-29]. Currently, both the US Preventive Task Force [30] and the ATA [13] do not recommend routine thyroid cancer screening in any population other than those defined as high-risk, which includes only patients with a history of radiation exposure or a family history of differentiated thyroid cancer.

Nielsen, et al.’s meta-analysis found a significantly elevated odds ratio for patients diagnosed with either cancer of developing the other, but these studies did not measure how much time passed between diagnoses [2]. Similarly, Dong, et al. and Bolf, et al. published studies examining possible etiologies for bi-directional synchronous and metachronous thyroid and breast cancer, each noting that additional studies are warranted to better understand how the two cancers are related [4,26]. Huang, et al. studied 13,978 patients with breast cancer and examined how many of them developed thyroid cancer, as well as when and of what histology were both cancers [3]. Their results showed that 17.4% of patients had their thyroid cancer diagnosed more than a year before their diagnosis of breast cancer, 30.0% had synchronous diagnosis, defined as within one year of each other, and 62.6% were diagnosed with thyroid cancer at least a year after their diagnosis of breast cancer. They concluded that there may be different mechanisms underlying synchronous and metachronous disease [3].

Considering the reverse case (thyroid cancer preceding breast cancer), there has also been interest in studying whether there is an increased risk of thyroid cancer survivors developing breast cancer [31-33]. In 2001, a single-center analysis published by Chen, et al. found a relative risk of 1.42 for developing breast cancer in thyroid cancer survivors [31]. A meta-analysis was published subsequently in 2007 by Subramanian, et al. in Thyroid that found a standardized incidence ratio (SIR) of 1.25 for thyroid cancer survivors of developing breast cancer [32]. Kim, et al. further found a SIR of 1.13 in their cohort and, importantly, that elevated risk was associated with a smaller tumor size [33].

The results observed in our study indicate that clinicians may reassure their patients if a PET-positive nodule is found during workup of breast cancer that no relationship between the two cancers has been found among women in the state of Arkansas. The recommendations set forth by the ATA [13] are sufficient for women in our state. If the patient hails from outside Arkansas, consider that recent research suggests an increased risk of developing thyroid cancer as a SPC.

Limitations of our study include how the data was obtained and how both breast and thyroid cancer have been diagnosed and treated over the extended period under consideration. As outlined in the introduction, a common scenario that prompts workup for thyroid cancer in patients with breast cancer is increased uptake on PET. However, the use of PET scans was not introduced as routine screening for metastatic disease in breast cancer until the late 1990’s [15,34], therefore many women may have developed clinical thyroid pathology that was not found earlier because they were never given a PET scan. Further, advancements in treatment of breast cancer have increased survivorship among women [17,18], and it is possible that women who would have developed thyroid cancer might have succumbed to their breast cancer prior to the possibility of developing a thyroid cancer if they were treated in the distant past [35].

The data for this project was extracted from the EPIC EMR, which was implemented in 2014 at UAMS. Owing to the large number of patients flagged with a diagnosis of thyroid pathology, a chart review was conducted only on patients who had both thyroid pathology and breast cancer. During the chart review process, the reviewer often relied on physician notes or reported patient recollection of dates of diagnosis and interventions. As a result, documentation of thyroid or breast pathology in these records may be inaccurate. For example, the specific type of pathology and date of diagnosis was not always recorded. Sometimes only the month or year of diagnosis was available, and receptor status for the breast cancer was sometimes incomplete or not recorded.

Conclusions

Among the patients in our study, there was no increased risk of developing either cancer in women in Arkansas. How-
ever, among women who did develop thyroid cancer after breast cancer, a positive family history was only found in 2
women, and of those 1 was diagnosed with thyroid cancer after breast cancer. The significant finding of a RR of 0.5 for
women with thyroid cancer of developing breast cancer sub-
sequently is surprising. These results may be valid exclusively
for the state of Arkansas. More work needs to be done to as-
sess whether there are regional differences in these relative
risks, which is currently being undertaken.

Whether they can be further generalised to the nation
is under investigation currently in collaboration with other
institutions through the Accrual to Clinical Trials (ACT) net-
work, with the cooperation of: University of California - Da-
vis, University of California - Irvine, University of Texas Health
Science Center at San Antonio, University of Kansas Medical
Center, University of Alabama - Birmingham, Pennsylvania
State University, University of California - San Francisco, Emo-
y University, and University of Kentucky.

Data Availability

Data for Figures 1 and 2:

(1999-2017): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Can-
cer Institute; www.cancer.gov/cancer/dataviz, released in June
2020.

Surveillance, Epidemiology, and End Results (SEER) Pro-
gram (www.seer.cancer.gov) SEER*Stat Database: Incidence
- Linked To County Attributes - Time Dependent (1990-2017)
Income/Rurality, 1969-2017 Counties, National Cancer Insti-
tute, DCCPS, Surveillance Research Program, released April
2020, based on the November 2019 submission.

Age-Adjusted Cancer Incidence Rates in Arkansas, 2000-
cancer-rates.info/ar/>

Data from our study is available upon request. Contact Dr.
Deanne King at DKing3@uams.edu.

Conflicts of Interest

The author(s) declare(s) that there is no conflict of inter-
est regarding the publication of this paper.

Funding Statement

No funding.

Acknowledgments

None.

Supplementary Materials

None.

References


Visualizations Tool, based on November 2018 submission data
(1999-2017) U.S. Department of Health and Human Services,
Centers for Disease Control and Prevention and National Can-
cer Institute.

cancer link: A systematic review and meta-analysis. Cancer Epi-
demiol Biomarkers Prev 25: 231-238.

breast cancer and thyroid cancer: A study based on 13 978 pa-

tion between thyroid and breast carcinoma. World J Surg Oncol
16: 130.

tween breast cancer and thyroid cancer: A meta-analysis. Breast

American Cancer Society, Atlanta.

7. Stack BC Jr, Bodenner DL, Bartel TB, et al. (2012) Re: Thyroid in-
cidentalomas in FDG-PET/CT: Prevalence and clinical impact. Eur
Arch Otorhinolaryngol 269: 1873.

of a thyroid nodule be determined by positron emission tomog-

diffuse FDG uptake in the thyroid of patients with hypothyroid-

roid carcinoma in fluorodeoxyglucose positron emission tomog-
raphy-positive thyroid incidentalomas. Otolaryngol Head Neck
Surg 137: 400-404.

ificance of diffusely increased 18F-FDG uptake in the thyroid

Dartmouth (MA).

thyroid association management guidelines for adult patients
with thyroid nodules and differentiated thyroid cancer: The
American thyroid association guidelines task force on thyroid
nodules and differentiated thyroid cancer. Thyroid 26: 1-133.


guideline for tumor imaging with 18F-FDG PET/CT 1.0. Journal of

sideration of evaluation for hereditary cancer predisposition
syndromes and how they can change management. R I Med J

in Europe 1999-2007 by country and age: Results of EUROCARE:

society/American society of clinical oncology breast cancer sur-


